The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | BPd as a new SoC in R/R multiple myeloma based on findings from the DREAMM-8 trial
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, provides an update on the DREAMM-8 trial (NCT04484623), comparing belantamab mafodotin plus pomalidomide and dexamethasone (BPd) to pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory (R/R) multiple myeloma (MM). The BPd arm showed superior progression-free survival (PFS), complete response (CR) rates, and measurable residual disease (MRD) negativity, establishing BPd as a new standard of care (SoC) for patients previously treated with lenalidomide and daratumumab. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen, Sanofi, Regeneron, Celgene, Menarini, Takeda, GSK, BMS, Janssen, Beigene, Swixx, Astra Zeneca.
